Benzanilide derivatives

US5358948A · kind A · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• John Bradshaw · Solon, US
• John W. Clitherow · Sawbridgeworth, GB

Key dates

• Filing date: Sep 17, 1992
• Grant date: Oct 25, 1994
• Expiry date: Sep 17, 2012

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom, a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy; PA0 R.sup.2 represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, --CN, --NO.sub.2, --CO.sub.2.sup.6, --COR.sup.6, --CONR.sup.6 R.sup.7 and --(CH.sub.2).sub.m OC(O)C.sub.1-4 alkyl; PA0 R.sup.3 represents the group ##STR2## R.sup.4 and R.sup.5 which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C.sub.1-6 alkoxy and C.sub.1-6 alkyl; PA0 R.sup.6 R.sup.7 and R.sup.8, which may be the same or different, each independently represent a hydrogen atom or a C.sub.1-6 alkyl group; and m represents zero or an integer from 1 to 3. The compounds may be used in the treatment or prophylaxis of depression and other CNS disorders.